{"id":"astra-zeneca-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"50–70","effect":"Injection site pain"},{"rate":"50–60","effect":"Fatigue"},{"rate":"40–50","effect":"Headache"},{"rate":"30–40","effect":"Myalgia"},{"rate":"20–30","effect":"Fever"},{"rate":"10–20","effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL6068383","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to introduce the gene encoding the SARS-CoV-2 spike protein into host cells. This triggers both cellular (T-cell) and humoral (antibody) immune responses. The immune system then recognizes and attacks cells expressing the spike protein and neutralizes circulating virus.","oneSentence":"This viral vector vaccine delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate adaptive immune responses against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:36.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention"}]},"trialDetails":[{"nctId":"NCT05012943","phase":"PHASE2, PHASE3","title":"The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)","status":"COMPLETED","sponsor":"Vinbiocare Biotechnology Joint Stock Company","startDate":"2021-08-15","conditions":"COVID-19 Vaccines","enrollment":19474},{"nctId":"NCT05710783","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster.","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2022-11-09","conditions":"SARS-CoV-2 Infection","enrollment":4065},{"nctId":"NCT04894435","phase":"PHASE2","title":"Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2021-05-20","conditions":"COVID-19","enrollment":669},{"nctId":"NCT05028257","phase":"PHASE3","title":"Allergy and COVID-19 Vaccines","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-15","conditions":"Anaphylactic Reaction, Vaccine Reaction","enrollment":117},{"nctId":"NCT04760132","phase":"PHASE4","title":"National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)","status":"COMPLETED","sponsor":"Jens D Lundgren, MD","startDate":"2021-02-08","conditions":"SARS-CoV Infection","enrollment":7600},{"nctId":"NCT04742842","phase":"PHASE1","title":"The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2021-06-21","conditions":"SARS-CoV2 COVID-19","enrollment":68},{"nctId":"NCT04826770","phase":"","title":"Adaptive Immune Response to COVID-19 Vaccination","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2021-01-06","conditions":"SARS-CoV-2 Vaccination","enrollment":70},{"nctId":"NCT05618548","phase":"","title":"Vaccination Against COVID-19 in Pregnant and Lactating Women in Belgium","status":"UNKNOWN","sponsor":"Universiteit Antwerpen","startDate":"2021-03-01","conditions":"Covid19","enrollment":110},{"nctId":"NCT05074368","phase":"NA","title":"Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2021-07-06","conditions":"Healthy Adult Volunteers","enrollment":499},{"nctId":"NCT05408299","phase":"","title":"Comparative Study of Patterns of Immune Response to COVID 19 Vaccination","status":"UNKNOWN","sponsor":"National Research Centre, Egypt","startDate":"2022-06-20","conditions":"Immune Response to Covid 19 Vaccination","enrollment":100},{"nctId":"NCT04824651","phase":"","title":"Covid-19 Vaccine Cohort in Specific Populations","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-03-25","conditions":"Immune Deficiency","enrollment":6920},{"nctId":"NCT04811391","phase":"","title":"COVID-19 Vaccine Effectiveness in Albanian Health Workers","status":"UNKNOWN","sponsor":"Institute of Public Health, Albania","startDate":"2021-02-19","conditions":"Covid19","enrollment":1500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Astra Zeneca COVID-19 vaccine","genericName":"Astra Zeneca COVID-19 vaccine","companyName":"Vinbiocare Biotechnology Joint Stock Company","companyId":"vinbiocare-biotechnology-joint-stock-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"This viral vector vaccine delivers genetic instructions for the SARS-CoV-2 spike protein to stimulate adaptive immune responses against COVID-19. Used for COVID-19 prevention.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}